CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AZNCF

MEDI4736 (Durvalumab)+Tremelimumab

Phase 3
ASTRAZENECA PLC (AZNCF)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Non-Small-Cell Lung Carcinoma NSCLC

View Full Landscape
Drug Information

Target Indication

Non-Small-Cell Lung Carcinoma NSCLC

Clinical Trial

NCT02453282

Last updated: 2/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.